95 related articles for article (PubMed ID: 18957720)
41. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
42. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
43. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
44. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
[TBL] [Abstract][Full Text] [Related]
45. K-ras codon 12 mutations detected with enriched PCR method in operable non-small cell lung cancer.
Kovalchuk O; Chyczewska E; Niklinska W; Niklinski J; Naumnik W; Chyczewski L
Folia Histochem Cytobiol; 2001; 39 Suppl 2():68-9. PubMed ID: 11820632
[TBL] [Abstract][Full Text] [Related]
46. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
[TBL] [Abstract][Full Text] [Related]
47. Pleomorphic (giant and spindle cell) carcinoma is genetically distinct from adenocarcinoma and squamous cell carcinoma by K-ras-2 and p53 analysis.
Przygodzki RM; Koss MN; Moran CA; Langer JC; Swalsky PA; Fishback N; Bakker A; Finkelstein SD
Am J Clin Pathol; 1996 Oct; 106(4):487-92. PubMed ID: 8853037
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligands in non-small cell lung carcinoma patients.
Haghgoo SM; Khosravi A; Mortaz E; Pourabdollah-Toutkaboni M; Seifi S; Sabour S; Allameh A
Clin Biochem; 2017 Apr; 50(6):293-300. PubMed ID: 27923629
[TBL] [Abstract][Full Text] [Related]
49. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
50. Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features.
Capodanno A; Boldrini L; Proietti A; Alì G; Pelliccioni S; Niccoli C; D'Incecco A; Cappuzzo F; Chella A; Lucchi M; Mussi A; Fontanini G
Int J Oncol; 2013 Sep; 43(3):765-74. PubMed ID: 23820752
[TBL] [Abstract][Full Text] [Related]
51. Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.
Nakajima T; Yasufuku K; Nakagawara A; Kimura H; Yoshino I
Chest; 2011 Nov; 140(5):1319-1324. PubMed ID: 21527506
[TBL] [Abstract][Full Text] [Related]
52. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer.
Ferretti G; Curigliano G; Pastorino U; Cittadini A; Flamini G; Calabrò MG; De Pas T; Orlando L; Mandalà M; Colleoni M; Spaggiari L; Granone PL; Pagliari G; de Braud F; Fazio N; Goldhirsch A
Clin Cancer Res; 2000 Jun; 6(6):2393-400. PubMed ID: 10873091
[TBL] [Abstract][Full Text] [Related]
53. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers.
Li J; Hu YM; Wang Y; Tang XP; Shi WL; Du YJ
Int J Biol Markers; 2014 Dec; 29(4):e328-36. PubMed ID: 24519547
[TBL] [Abstract][Full Text] [Related]
54. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
[TBL] [Abstract][Full Text] [Related]
55. Decreased expression of ING2 gene and its clinicopathological significance in Chinese NSCLC patients.
Pan YQ; Zhang X; Xu DP; Bao WG; Lin AF; Xu HH; Yan WH
Neoplasma; 2014; 61(4):468-75. PubMed ID: 24712846
[TBL] [Abstract][Full Text] [Related]
56. Do molecular markers predict survival in non-small-cell lung cancer?
Greatens TM; Niehans GA; Rubins JB; Jessurun J; Kratzke RA; Maddaus MA; Niewoehner DE
Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1093-7. PubMed ID: 9563724
[TBL] [Abstract][Full Text] [Related]
57. Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma.
Strazisar M; Mlakar V; Rott T; Glavac D
Cancer Invest; 2009 May; 27(4):407-16. PubMed ID: 19229701
[TBL] [Abstract][Full Text] [Related]
58. Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification.
Seki K; Suda T; Aoyagi Y; Sugawara S; Natsui M; Motoyama H; Shirai Y; Sekine T; Kawai H; Mita Y; Waguri N; Kuroiwa T; Igarashi M; Asakura H
Clin Cancer Res; 2001 Jul; 7(7):1976-81. PubMed ID: 11448913
[TBL] [Abstract][Full Text] [Related]
59. [p53 alterations in human lung cancer and their correlation with clinicopathological features and prognosis].
Zhang J; Zheng J; Fang W
Zhonghua Bing Li Xue Za Zhi; 1998 Aug; 27(4):286-9. PubMed ID: 11244999
[TBL] [Abstract][Full Text] [Related]
60. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours.
Lantuejoul S; Soria JC; Moro-Sibilot D; Morat L; Veyrenc S; Lorimier P; Brichon PY; Sabatier L; Brambilla C; Brambilla E
Br J Cancer; 2004 Mar; 90(6):1222-9. PubMed ID: 15026805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
